Results
1 -
10 of
39
(Click
here to explore results)
- Mechanisms and Metal Involvement in Neurodegenerative Diseases, CHAPTER 3 Parkinson’s Disease: Involvement of Iron and Oxidative Stress. David T. Dexter
, 2013
, Pages 58-79
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 3 Dopaminergic Treatments for Parkinson’s Disease: Light and Shadows. Nicola Simola
, 2013
, Pages 61-82
- Oxidative Stress and Redox Signalling in Parkinson’s Disease, CHAPTER 3 Mitochondrial Dysfunction in Parkinson’s Disease. Manisha Patel, Pallavi Bhuyan McElroy
, 2017
, Pages 61-96
- Cyclodextrins in Chromatography, Use of Cyclodextrins in Electrophoretic Techniques. Tibor Cserháti, Esther Forgács
, 2003
, Pages 79-152
- Biomedical Imaging: The Chemistry of Labels, Probes and Contrast Agents, Chapter 3 Recent Developments in PET and SPECT Radioligands for CNS Imaging. David Alagille, Ronald M. Baldwin, Gilles D. Tamagnan
, 2012
, Pages 49-143
- Forensic Chemistry of Substance Misuse: A Guide to Drug Control (2), CHAPTER 15 Amphetamine, Methylamphetamine and MDMA
, 2022
, Pages 204-211
- Designing Multi-Target Drugs, Chapter 18 Discovery of Multi-Target Agents for Neurological Diseases via Ligand Design. Maria Laura Bolognesi, Carlo Melchiorre, Cornelis J. Van der Schyf, Moussa Youdim
, 2012
, Pages 290-315
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 13 5‐HT1A Receptors as a Therapeutic Target for Parkinson’s Disease. Saki Shimizu, Yukihiro Ohno
, 2013
, Pages 308-326
- Emerging Drugs and Targets for Parkinson's Disease, CHAPTER 5 Pharmacologic Management of Dopaminergic‐Induced Dyskinesias in Parkinson’s Disease. Mildred D. Gottwald, Michael J. Aminoff
, 2013
, Pages 110-125
- Drug Discovery for Psychiatric Disorders, CHAPTER 13 Therapeutic Approaches to Bipolar Disorder. Moghis U. Ahmad, Shoukath M. Ali, Saifuddin Sheikh, Ateeq Ahmad, Imran Ahmad
, 2012
, Pages 333-356